Medications development to treat alcohol dependence: a vision for the next decade.
Medications development to treat alcohol dependence: a vision for the next decade.
复制标题
DOI：
10.1111/j.1369-1600.2012.00454.x
复制
发表时间：
2012-05
影响因子：
3.4
通讯作者：
Noronha A
中科院分区：
文献类型：
--
作者：
Litten RZ;Egli M;Heilig M;Cui C;Fertig JB;Ryan ML;Falk DE;Moss H;Huebner R;Noronha A
据估计，全世界有超过7600万人患有可诊断的酒精使用障碍（AUD）（酒精滥用或依赖），使这些疾病成为一个主要的全球健康问题。药物治疗为治疗AUD提供了很有前途的手段，在过去20年中取得了重大进展。在过去的二十年里，美国食品和药物管理局批准了四种治疗酒精中毒的药物中的三种。不幸的是，这些药物并不适用于所有人，因此需要个性化的方法来优化临床获益或更有效的药物，以治疗更广泛的患者，或两者兼而有之。为了促进全球健康，美国国立卫生研究院（NIH）的潜在重组必须继续支持国家酒精滥用和酒精中毒研究所（NIAAA）的愿景，即确保在未来十年开发和提供新的和更有效的药物来治疗AUD。为了实现这一目标，NIAAA药物开发团队确定了三个基本的长期目标：1）使药物开发过程更有效; 2）确定更有效的药物，个性化治疗方法，或两者兼而有之; 3）促进药物在现实世界治疗环境中的实施和适应。这些目标将通过七个关键目标来实现。本文件从原理和战略的角度阐述了这些目标。这些目标的成功实施将导致开发更有效和安全的药物，提供更多的治疗选择，并最终减轻这种毁灭性疾病的影响。
More than 76 million people worldwide are estimated to have diagnosable Alcohol Use Disorders (AUDs) (alcohol abuse or dependence), making these disorders a major global health problem. Pharmacotherapy offers promising means for treating AUDs, and significant progress has been made in the past 20 years. The U.S. Food and Drug Administration approved three of the four medications for alcoholism in the last two decades. Unfortunately, these medications do not work for everyone, prompting the need for a personalized approach to optimize clinical benefit or more efficacious medications that can treat a wider range of patients, or both. To promote global health, the potential reorganization of the National Institutes of Health (NIH) must continue to support the National Institute on Alcohol Abuse and Alcoholism’s (NIAAA’s) vision of ensuring the development and delivery of new and more efficacious medications to treat AUDs in the coming decade. To achieve this objective, the NIAAA Medications Development Team has identified three fundamental long-range goals: 1) to make the drug development process more efficient; 2) to identify more efficacious medications, personalize treatment approaches, or both, and 3) to facilitate the implementation and adaptation of medications in real-world treatment settings. These goals will be carried out through seven key objectives. This paper describes those objectives in terms of rationale and strategy. Successful implementation of these objectives will result in the development of more efficacious and safe medications, provide a greater selection of therapy options, and ultimately lessen the impact of this devastating disorder.
登录
查看更多内容
影响因子：
8.2
作者：
George, Olivier;Koob, George F.
通讯作者：
Koob, George F.
影响因子：
3.4
作者：
Anton, RF;Drobes, DJ;Moak, D
通讯作者：
Moak, D
影响因子：
4.2
作者：
Dawson, Deborah A.;Li, Ting-Kai;Grant, Bridget F.
通讯作者：
Grant, Bridget F.
影响因子：
17.1
作者：
Collins, Francis S.
通讯作者：
Collins, Francis S.
影响因子：
2.9
作者：
Anton, Raymond F.;Kranzler, Henry;Han, Jian
通讯作者：
Han, Jian